APA (7th ed.) Citation

A, K., JE, T., K, O., JG, C., S, Z., J, B., . . . RA, B. (2012). Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 18(18), 5031. https://doi.org/10.1158/1078-0432.CCR-12-0453

Chicago Style (17th ed.) Citation

A, Kirane, Toombs JE, Ostapoff K, Carbon JG, Zaknoen S, Braunfeld J, Schwarz RE, Burrows FJ, and Brekken RA. "Apricoxib, a Novel Inhibitor of COX-2, Markedly Improves Standard Therapy Response in Molecularly Defined Models of Pancreatic Cancer." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 18, no. 18 (2012): 5031. https://doi.org/10.1158/1078-0432.CCR-12-0453.

MLA (9th ed.) Citation

A, Kirane, et al. "Apricoxib, a Novel Inhibitor of COX-2, Markedly Improves Standard Therapy Response in Molecularly Defined Models of Pancreatic Cancer." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 18, no. 18, 2012, p. 5031, https://doi.org/10.1158/1078-0432.CCR-12-0453.